Home  |   Companies  |   Targets  |   Drugs  |   Diseases  |   Search  |   Help  |   About Blog Blog | Twitter Twitter | Rss SciBite News | Contact Contact   
LogoBeta Software
Open Drug Discovery Intelligence
searchSearch Scibite.com

Targets, Diseases & Drug Names All News
a- A+

Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma
Tue Apr 24 13:32:44 BST 2012
Key Topics

Click on any of the topic names to view its own newsletter. The text we matched to the topic is shown in grey underneath.



 Renal Cell Carcinoma




 Barrett Esophagus

[matched:barrett esophagus]

Other Topics Mentioned

Less relevant than those above but listed here for convenience.

 Cleidocranial Dysplasia


Altmetric Article Ranking
Altmetric is a new way of monitoring impact of journal articles across social media, provided by altmetric.com. Click on the badge to see more information about this article from Altmetric.

Barrett esophagus is the precancerous lesion leading to Barrett adenocarcinoma. The natural history of Barrett metaplasia and its neoplastic progression are still controversial. Anterior gradient 2 is up-regulated in both Barrett intestinal metaplasia and Barrett adenocarcinoma, but no information is available on anterior gradient 2 expression in the spectrum of the phenotypic changes occurring in the natural history of Barrett adenocarcinoma (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia [formerly called low-grade dysplasia], and high-grade intraepithelial neoplasia [formerly called high-grade dysplasia]). Applying immunohistochemistry and reverse transcription and quantitative real-time polymerase chain reaction, this study addressed the role of anterior gradient 2 in Barrett carcinogenesis. Anterior gradient 2 expression was assessed semiquantitatively in 125 consecutive biopsy samples in the adenocarcinoma spectrum arising in Barrett esophagus (Barrett esophagus cardiac-type metaplasia, 25; Barrett esophagus intestinal metaplasia, 25; low-grade intraepithelial neoplasia, 25; high-grade intraepithelial neoplasia, 25; Barrett adenocarcinoma, 25). Additional biopsy samples of esophageal squamous mucosa (n = 25) served as controls. Anterior gradient 2 messenger RNA expression was also tested (reverse transcription and quantitative real-time polymerase chain reaction) in a different series of 40 samples (esophageal squamous mucosa, 10; Barrett esophagus cardiac-type metaplasia, 10; Barrett esophagus intestinal metaplasia, 10; Barrett adenocarcinoma, 10). Anterior gradient 2 was never expressed in squamous esophageal epithelium but consistently overexpressed (to much the same degree) in the whole spectrum of Barrett disease (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and Barrett adenocarcinoma). Anterior gradient 2 messenger RNA was expressed significantly more in Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, and Barrett adenocarcinoma than in native squamous epithelium (P < .001), with no significant differences between the 3 groups. Anterior gradient 2 overexpression affects the whole spectrum of the metaplastic/neoplastic lesions involved in Barrett carcinogenesis. This study supports the biological similarity of the nonintestinal and intestinal types of Barrett metaplasia as precursors of Barrett adenocarcinoma;   Read more on this story here

Source: ncbi.nlm.nih.gov   (view original)
Inst: Department of Medical Diagnostic Sciences and Special Therapies, Surgical Pathology and Cytopathology Unit, University of Padova, 35100 Padova, Italy.
   abstracted provided by MEDLINE/PubMed, a database of the U.S. National Library of Medicine.

Summary Loaded